Literature DB >> 30563338

Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2- d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5.

Duy Nguyen1, Clara Lemos1, Lars Wortmann1, Knut Eis1, Simon J Holton1, Ulf Boemer1, Dieter Moosmayer1, Uwe Eberspaecher1, Joerg Weiske1, Christian Lechner1, Stefan Prechtl1, Detlev Suelzle1, Franziska Siegel1, Florian Prinz1, Ralf Lesche1, Barbara Nicke1, Katrin Nowak-Reppel1, Herbert Himmel1, Dominik Mumberg1, Franz von Nussbaum1, Carl F Nising1, Marcus Bauser1, Andrea Haegebarth1.   

Abstract

The availability of a chemical probe to study the role of a specific domain of a protein in a concentration- and time-dependent manner is of high value. Herein, we report the identification of a highly potent and selective ERK5 inhibitor BAY-885 by high-throughput screening and subsequent structure-based optimization. ERK5 is a key integrator of cellular signal transduction, and it has been shown to play a role in various cellular processes such as proliferation, differentiation, apoptosis, and cell survival. We could demonstrate that inhibition of ERK5 kinase and transcriptional activity with a small molecule did not translate into antiproliferative activity in different relevant cell models, which is in contrast to the results obtained by RNAi technology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30563338     DOI: 10.1021/acs.jmedchem.8b01606

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

1.  Identification of the Highly Active, Species Cross-Reactive Complex I Inhibitor BAY-179.

Authors:  Jeffrey Mowat; Alexander H M Ehrmann; Sven Christian; Carolyn Sperl; Stephan Menz; Judith Günther; Roman C Hillig; Marcus Bauser; Wolfgang Schwede
Journal:  ACS Med Chem Lett       Date:  2022-02-18       Impact factor: 4.345

2.  BAY-885, a mitogen-activated protein kinase kinase 5 inhibitor, induces apoptosis by regulating the endoplasmic reticulum stress/Mcl-1/Bim pathway in breast cancer cells.

Authors:  Lei Wang; Xiaochun Ji; Chenxiao Mao; Rui Yu
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

3.  Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor.

Authors:  Duncan C Miller; Tristan Reuillon; Lauren Molyneux; Timothy Blackburn; Simon J Cook; Noel Edwards; Jane A Endicott; Bernard T Golding; Roger J Griffin; Ian Hardcastle; Suzannah J Harnor; Amy Heptinstall; Pamela Lochhead; Mathew P Martin; Nick C Martin; Stephanie Myers; David R Newell; Richard A Noble; Nicole Phillips; Laurent Rigoreau; Huw Thomas; Julie A Tucker; Lan-Zhen Wang; Michael J Waring; Ai-Ching Wong; Stephen R Wedge; Martin E M Noble; Celine Cano
Journal:  J Med Chem       Date:  2022-04-25       Impact factor: 8.039

Review 4.  Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy.

Authors:  Xiaoli Pan; Junping Pei; Aoxue Wang; Wen Shuai; Lu Feng; Faqian Bu; Yumeng Zhu; Lan Zhang; Guan Wang; Liang Ouyang
Journal:  Acta Pharm Sin B       Date:  2022-01-04       Impact factor: 14.903

Review 5.  Beyond Kinase Activity: ERK5 Nucleo-Cytoplasmic Shuttling as a Novel Target for Anticancer Therapy.

Authors:  Alessandro Tubita; Zoe Lombardi; Ignazia Tusa; Persio Dello Sbarba; Elisabetta Rovida
Journal:  Int J Mol Sci       Date:  2020-01-31       Impact factor: 5.923

6.  Solution Conformations Shed Light on PROTAC Cell Permeability.

Authors:  Yoseph Atilaw; Vasanthanathan Poongavanam; Caroline Svensson Nilsson; Duy Nguyen; Anja Giese; Daniel Meibom; Mate Erdelyi; Jan Kihlberg
Journal:  ACS Med Chem Lett       Date:  2020-12-25       Impact factor: 4.345

7.  ERK5 signalling pathway is a novel target of sorafenib: Implication in EGF biology.

Authors:  Marta Ortega-Muelas; Olga Roche; Diego M Fernández-Aroca; José A Encinar; David Albandea-Rodríguez; Elena Arconada-Luque; Raquel Pascual-Serra; Ismael Muñoz; Isabel Sánchez-Pérez; Borja Belandia; María J Ruiz-Hidalgo; Ricardo Sánchez-Prieto
Journal:  J Cell Mol Med       Date:  2021-10-16       Impact factor: 5.310

8.  Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles.

Authors:  John K Eaton; Laura Furst; Richard A Ruberto; Dieter Moosmayer; André Hilpmann; Matthew J Ryan; Katja Zimmermann; Luke L Cai; Michael Niehues; Volker Badock; Anneke Kramm; Sixun Chen; Roman C Hillig; Paul A Clemons; Stefan Gradl; Claire Montagnon; Kiel E Lazarski; Sven Christian; Besnik Bajrami; Roland Neuhaus; Ashley L Eheim; Vasanthi S Viswanathan; Stuart L Schreiber
Journal:  Nat Chem Biol       Date:  2020-03-30       Impact factor: 15.040

9.  The MEK5-ERK5 Kinase Axis Controls Lipid Metabolism in Small-Cell Lung Cancer.

Authors:  Sandra Cristea; Garry L Coles; Daniel Hornburg; Maya Gershkovitz; Julia Arand; Siqi Cao; Triparna Sen; Stuart C Williamson; Jun W Kim; Alexandros P Drainas; Andrew He; Laurent Le Cam; Lauren Averett Byers; Michael P Snyder; Kévin Contrepois; Julien Sage
Journal:  Cancer Res       Date:  2020-01-22       Impact factor: 12.701

Review 10.  Small molecule ERK5 kinase inhibitors paradoxically activate ERK5 signalling: be careful what you wish for….

Authors:  Simon J Cook; Julie A Tucker; Pamela A Lochhead
Journal:  Biochem Soc Trans       Date:  2020-10-30       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.